Allison Gamboa Hays

Allison Gamboa Hays

Auto-generated profile, based on publicly available information

Allison Gamboa Hays

Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Journal of the American Heart Association
Verified
Journal Article
Closed access
YKYaa A. Kwapong
Yaa A. Kwapong
EBEllen Boakye
Ellen Boakye
SKSadiya S. Khan
Sadiya S. Khan
MHMichael C. Honigberg
Michael C. Honigberg
SMSeth S. Martin
Seth S. Martin
GSGarima Sharma
Garima Sharma
Background: Depression is a nontraditional risk factor for cardiovascular disease (CVD). Data on the association of depression and poor mental health with CVD and suboptimal cardiovascular health (CVH) among young adults are limited. Methods and Results: We used data from 593 616 young adults (aged 18–49 years) from the 2017 to 2020 Behavioral Risk Factor Surveillance System, a nationally representative survey of noninstitutionalized US adults. Exposures were self‐reported depression and poor mental health days (PMHDs; categorized as 0, 1–13, and 14–30 days of poor mental health in the past 30 days). Outcomes were self‐reported CVD (composite of myocardial infarction, angina, or stroke) and suboptimal CVH (≥2 cardiovascular risk factors: hypertension, hypercholesterolemia, overweight/obesity, smoking, diabetes, physical inactivity, and inadequate fruit and vegetable intake). Using logistic regression, we investigated the association of depression and PMHDs with CVD and suboptimal CVH, adjusting for sociodemographic factors (and cardiovascular risk factors for the CVD outcome). Of the 593 616 participants (mean age, 34.7±9.0 years), the weighted prevalence of depression was 19.6% (95% CI, 19.4–19.8), and the weighted prevalence of CVD was 2.5% (95% CI, 2.4–2.6). People with depression had higher odds of CVD than those without depression (odds ratio [OR], 2.32 [95% CI, 2.13–2.51]). There was a graded association of PMHDs with CVD. Compared with individuals with 0 PMHDs, the odds of CVD in those with 1 to 13 PMHDs and 14 to 30 PHMDs were 1.48 (95% CI, 1.34–1.62) and 2.29 (95% CI, 2.08–2.51), respectively, after adjusting for sociodemographic and cardiovascular risk factors. The associations did not differ significantly by sex or urban/rural status. Individuals with depression had higher odds of suboptimal CVH (OR, 1.79 [95% CI, 1.65–1.95]) compared with those without depression, with a similar graded relationship between PMHDs and suboptimal CVH. Conclusions: Depression and poor mental health are associated with premature CVD and suboptimal CVH among young adults. Although this association is likely bidirectional, prioritizing mental health may help reduce CVD risk and improve CVH in young adults.

9 February 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
TMThomas S. Metkus
Thomas S. Metkus
LSLori J Sokoll
Lori J Sokoll
ABAndreas S. Barth
Andreas S. Barth
MCMatthew J. Czarny
Matthew J. Czarny
AHAllison G. Hays
Allison G. Hays
RHRani K. Hasan
Rani K. Hasan
Background: Knowledge gaps remain in the epidemiology and clinical implications of myocardial injury in coronavirus disease 2019 (COVID-19). We aimed to determine the prevalence and outcomes of myocardial injury in severe COVID-19 compared with acute respiratory distress syndrome (ARDS) unrelated to COVID-19. Methods: We included intubated patients with COVID-19 from 5 hospitals between March 15 and June 11, 2020, with troponin levels assessed. We compared them with patients from a cohort study of myocardial injury in ARDS and performed survival analysis with primary outcome of in-hospital death associated with myocardial injury. In addition, we performed linear regression to identify clinical factors associated with myocardial injury in COVID-19. Results: Of 243 intubated patients with COVID-19, 51% had troponin levels above the upper limit of normal. Chronic kidney disease, lactate, ferritin, and fibrinogen were associated with myocardial injury. Mortality was 22.7% among patients with COVID-19 with troponin under the upper limit of normal and 61.5% for those with troponin levels >10 times the upper limit of normal ( P <0.001). The association of myocardial injury with mortality was not statistically significant after adjusting for age, sex, and multisystem organ dysfunction. Compared with patients with ARDS without COVID-19, patients with COVID-19 were older and had higher creatinine levels and less favorable vital signs. After adjustment, COVID-19–related ARDS was associated with lower odds of myocardial injury compared with non–COVID-19–related ARDS (odds ratio, 0.55 [95% CI, 0.36–0.84]; P =0.005). Conclusions: Myocardial injury in severe COVID-19 is a function of baseline comorbidities, advanced age, and multisystem organ dysfunction, similar to traditional ARDS. The adverse prognosis of myocardial injury in COVID-19 relates largely to multisystem organ involvement and critical illness.

8 June 2021 in Hypertension
Verified
Journal Article
Closed access
PDF file
AMAnum S. Minhas
Anum S. Minhas
SOS. Michelle Ogunwole
S. Michelle Ogunwole
AVArthur Jason Vaught
Arthur Jason Vaught
PWPensee Wu
Pensee Wu
MMMamas A. Mamas
Mamas A. Mamas
EMErin D. Michos
Erin D. Michos
Women with pregnancy-induced hypertension, defined as gestational hypertension and preeclampsia/eclampsia, are at increased risk of long-term cardiovascular disease, but less is known about the spectrum of acute cardiovascular outcomes, especially across racial/ethnic groups. We evaluated the risk of cardiovascular events at delivery associated with gestational hypertension and preeclampsia/eclampsia, compared with no pregnancy-induced hypertension, overall and by race/ethnicity. We used the 2016 to 2018 National Inpatient Sample data. International Classification of Diseases , Tenth Revision , Clinical Modification codes identified delivery hospitalizations and clinical diagnoses. Using survey weights, cardiovascular events were examined using logistic regression by pregnancy-induced hypertension status, with subsequent stratification by race/ethnicity. Among 11 304 996 deliveries in 2016 to 2018, gestational hypertension occurred in 614 995 (5.4%) and preeclampsia in 593 516 (5.2%). Black women had higher odds for preeclampsia independent of underlying comorbidities (adjusted odds ratio, 1.45 [95% CI, 1.42–1.49]) and had the highest rates for several complications (peripartum cardiomyopathy, 506; heart failure, 660; acute renal failure, 953; and arrhythmias, 418 per 100 000 deliveries). After adjustment for socioeconomic factors and comorbidities, preeclampsia/eclampsia was associated with increased risk of cardiovascular events in women of all races/ethnicities. However, risk was highest among Asian/Pacific Islander women and lowest among Black women. In sum, while Black women were the most likely to experience preeclampsia, Asian/Pacific women were the most at risk for acute cardiovascular complications during delivery hospitalization.

21 July 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TLThorsten M. Leucker
Thorsten M. Leucker
GGGary Gerstenblith
Gary Gerstenblith
MSMichael Schär
Michael Schär
TBTodd T. Brown
Todd T. Brown
SJSteven R. Jones
Steven R. Jones
AHAllison G. Hays
Allison G. Hays
Background: PCSK9 (proprotein convertase subtilisin/kexin type 9) is well recognized for its important role in cholesterol metabolism. Elevated levels are associated with increased cardiovascular risk and inhibition with PCSK9 antibodies (PCSK9i) lowers cardiovascular events in patients with coronary artery disease. PCSK9 levels are also elevated in people living with HIV (PLWH) and those with dyslipidemia. Because increased PCSK9 in PLWH is associated with impaired coronary endothelial function, a barometer of coronary vascular health, we tested the hypothesis that PCSK9i improves impaired coronary endothelial function in dyslipidemia without coronary artery disease and in PLWH with nearly optimal/above goal low‐density lipoprotein cholesterol levels. Methods and Results: We performed a single‐center study in 19 PLWH and 11 with dyslipidemia to evaluate the effects of the PCSK9i evolocumab on coronary endothelial function using cine 3T MRI to noninvasively measure coronary endothelial function, assessed as the changes in coronary cross‐sectional area and coronary blood flow from rest to that during isometric handgrip exercise, a known endothelial‐dependent vasodilator. Before evolocumab, there was a decrease or no coronary vasodilation and no increase in coronary blood flow (the normal responses) to isometric handgrip exercise in either group. Following 6 weeks of evolocumab, 480 mg q4 weeks, the % cross‐sectional area changes from rest to isometric handgrip exercise were +5.6±5.5% and +4.5±3.1% in the PLWH and dyslipidemia groups, respectively, both P <0.01 versus baseline. Improved cross‐sectional area was paralleled by a significant coronary blood flow improvement in both groups. Conclusions: To our knowledge, these data represent the first evidence that PCSK9 inhibition improves coronary artery health in PLWH and people with dyslipidemia. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03500302.

2 October 2018 in Journal of the American Heart Association
Verified
Journal Article
Open access
TLThorsten M. Leucker
Thorsten M. Leucker
RWRobert G. Weiss
Robert G. Weiss
MSMichael Schär
Michael Schär
GBGabriele Bonanno
Gabriele Bonanno
LMLena Mathews
Lena Mathews
AHAllison G. Hays
Allison G. Hays
Background: HIV + people are at increased risk of coronary artery disease, but the responsible mechanisms are incompletely understood. Proprotein convertase subtilisin/kexin type 9 ( PCSK 9) is traditionally recognized for its importance in cholesterol metabolism; however, recent data suggest an additional, low‐density lipoprotein receptor–independent adverse effect on endothelial cell inflammation and function. We tested the hypotheses that PCSK 9 levels are increased and that abnormal coronary endothelial function is related to PCSK 9 serum levels in HIV + individuals. Methods and Results: Forty‐eight HIV + participants receiving antiretroviral therapy with suppressed viral replication, without coronary artery disease, and 15 age‐ and low‐density lipoprotein cholesterol–matched healthy HIV− subjects underwent magnetic resonance imaging to measure coronary endothelial function, quantified as percentage change in coronary artery cross‐sectional area during isometric handgrip exercise, an endothelial‐dependent stressor; and blood was obtained for serum PCSK 9 and systemic vascular biomarkers. Data are presented as mean±SD. Mean serum PCSK 9 was 65% higher in the HIV + subjects (302±146 ng/ mL ) than in the HIV − controls (183±52 ng/ mL , P <0.0001). Coronary endothelial function was significantly reduced in the HIV + versus HIV − subjects (percentage change in coronary artery cross‐sectional area, 2.9±9.6% versus 11.1±3.7%; P <0.0001) and inversely related to PCSK 9 ( R =−0.51, P <0.0001). Markers of endothelial activation and injury, P‐selectin and thrombomodulin, were also significantly increased in the HIV + subjects; and P‐selectin was directly correlated with serum PCSK 9 ( R =0.31, P =0.0144). Conclusions: Serum PCSK 9 levels are increased in treated HIV + individuals and are associated with abnormal coronary endothelial function, an established measure of vascular health.

2 July 2025 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
CLChangxin Lai
Changxin Lai
MYMinglang Yin
Minglang Yin
EKEugene G. Kholmovski
Eugene G. Kholmovski
DPDan M. Popescu
Dan M. Popescu
DLDai-Yin Lu
Dai-Yin Lu
NTNatalia A. Trayanova
Natalia A. Trayanova
Sudden cardiac death from ventricular arrhythmias is a leading cause of mortality worldwide. Arrhythmic death prognostication is challenging in patients with hypertrophic cardiomyopathy (HCM), a setting where current clinical guidelines show low performance and inconsistent accuracy. Here, we present a deep learning approach, MAARS (Multimodal Artificial intelligence for ventricular Arrhythmia Risk Stratification), to forecast lethal arrhythmia events in patients with HCM by analyzing multimodal medical data. MAARS’ transformer-based neural networks learn from electronic health records, echocardiogram and radiology reports, and contrast-enhanced cardiac magnetic resonance images, the latter being a unique feature of this model. MAARS achieves an area under the curve of 0.89 (95% confidence interval (CI) 0.79–0.94) and 0.81 (95% CI 0.69–0.93) in internal and external cohorts and outperforms current clinical guidelines by 0.27–0.35 (internal) and 0.22–0.30 (external). In contrast to clinical guidelines, it demonstrates fairness across demographic subgroups. We interpret MAARS’ predictions on multiple levels to promote artificial intelligence transparency and derive risk factors warranting further investigation.